1. Enhanced antitumor activity of irofulven in combination with irinotecan in pediatric solid tumor xenograft models

   • Michael H. Woo
   • Jennifer K. Peterson
   • Peter J. Houghton

   Original Article 16 October 2004 Pages: 411 - 419

   

2. Uptake of irinotecan metabolite SN-38 by the human intestinal cell line Caco-2

   • Tatsuya Itoh
   • Shirou Itagaki
   • Ken Iseki

   Original Article 23 November 2004 Pages: 420 - 424

   

3. Antitumor activity of albendazole against the human colorectal cancer cell line HT-29: in vitro and in a xenograft model of peritoneal carcinomatosis

   • Mohammad H. Pourgholami
   • Javed Akhter
   • David L. Morris

   Original Article 23 November 2004 Pages: 425 - 432

   

4. Development of a pharmacokinetic limited sampling model for temozolomide and its active metabolite MTIC

   • Mark N. Kirstein
   • John C. Panetta
   • Clinton F. Stewart

   Original Article 26 January 2005 Pages: 433 - 438

   

5. Hypericin—an inhibitor of proteasome function

   • F Pajonk
   • J Scholber
   • B Fiebich

   Original Article 26 January 2005 Pages: 439 - 446

   

6. In vivo antitumor activity by 2′,4′-dihydroxy-6′-methoxy-3′,5′-dimethylchalcone in a solid human carcinoma xenograft model

   • Chun-Lin Ye
   • Jian-Wen Liu
   • Feng Qian

   Original Article 22 January 2005 Pages: 447 - 452

   

7. A phase I, dose-finding study of irinotecan (CPT-11) short i.v. infusion combined with fixed dose of 5-fluorouracil (5-FU) protracted i.v. infusion in adult patients with advanced solid tumours

   • Javier Sastre
   • Luis Paz-Ares
   • Eduardo Díaz-Rubio

   Original Article 26 October 2004 Pages: 453 - 460

   

8. EM012, a microtubule-interfering agent, inhibits the progression of multidrug-resistant human ovarian cancer both in cultured cells and in athymic nude mice

   • Jun Zhou
   • Min Liu
   • Harish C. Joshi

   Original Article 03 February 2005 Pages: 461 - 465

   

9. Phase I trial of weekly docetaxel with a 4-weekly cisplatin administration in patients with advanced gastric carcinoma

   • Aristides Polyzos
   • Konstantinos Syrigos
   • Vassilios Georgoulias

   Original Article 20 January 2005 Pages: 466 - 470

10. Endoxifen (4-hydroxy-N-desmethyl-tamoxifen) has anti-estrogenic effects in breast cancer cells with potency similar to 4-hydroxy-tamoxifen

    • Young Chai Lim
    • Zeruesenay Desta
    • Todd C. Skaar

    Original Article 01 February 2005 Pages: 471 - 478

    

11. Effects of docetaxel on antigen presentation-related functions of human monocyte-derived dendritic cells

    • Hiroshi Nakashima
    • Akira Tasaki
    • Mitsuo Katano

    Original Article 23 February 2005 Pages: 479 - 487

    

12. Pharmacokinetics of low-dose doxorubicin and metabolites in patients with AIDS-related Kaposi sarcoma

    • M. Joerger
    • A. D. R. Huitema
    • J. H. Beijnen

    Original Article 23 February 2005 Pages: 488 - 496

    

13. Phase I study of the novel taxane CT-2103 in patients with advanced solid tumors

    • Maria Luisa Veronese
    • Keith Flaherty
    • Peter J. O’Dwyer

    Original Article 12 February 2005 Pages: 497 - 501

    

14. Secretory transport of irinotecan metabolite SN-38 across isolated intestinal tissue

    • Shirou Itagaki
    • Yoshinobu Sumi
    • Ken Iseki

    Short Communication 12 February 2005 Pages: 502 - 506

    

15. Significant induction of cyclophosphamide and thiotepa metabolism by phenytoin

    • Milly E. de Jonge
    • Alwin D. R. Huitema
    • Sjoerd Rodenhuis

    Short Communication 01 February 2005 Pages: 507 - 510